Proteomic Analysis of Patients Undergoing Bariatric Surgery

Get Involved

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Study Purpose

The expression of proteins in the blood of obese individuals is different from the expression of proteins in healthy individuals, and is also different in individuals after bariatric surgery. Therefore, this research aims to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-operative status. The objective of this research is to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-surgery status.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- patients over 18 years of age with a BMI above 35 kg/m² associated with comorbidity or BMI above 40 kg/m² without comorbidities,
Exclusion Criteria:
- Patients with a previous history of cancer; - Underage patients.

- Patients with other diseases predisposing to the development of cancer: cirrhosis, ulcerative colitis, Barrett's esophagus, etc. - Patients who have previously undergone bariatric surgery;

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06787807
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Universidade Federal de Pernambuco
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Álvaro B Ferraz, Doctor
Principal Investigator Affiliation	UFPE
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries	Brazil
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Obesity, Colon Cancer, Thyroid Cancer, Esophageal Cancer, Pancreatic Cancer, Gastric Cancer, Potmenopausal Breast Cancer, Endometrial Cancer, Liver Cancer, Gallbladder Cancer, Prostate Cancer, Ovarian, Kidney Cancer, Multiple Myeloma, Meningioma, Breast Cancer, Ovarian Cancer

Additional Details

The objective of this study is to analyze the Proteomics of obese patients in the preoperative context of bariatric surgery to evaluate which are the up-regulated proteins

- potentially related to oncogenic metabolic pathways - and also the down-regulated proteins in the context of obesity - potentially protective in the context of cancer.

As well as, evaluate the variation of these proteins, as well as the metabolic pathways with which they are associated, after weight loss promoted by bariatric surgery, in the period of 01 year after this intervention. The proteomic study will be carried out based on the formation of pools organized based on the patients' pre- and postoperative similarities. Proteomic analyzes will be carried out on a high-performance liquid chromatography system (nanoUPLC) model Acquity Mclass, Waters. Coupled to a Quadrupole Mass Spectrometer-Time of Flight (QToF) Model Sunapt Xs, Waters. Finally, the raw data (raw mass spectra) will be analyzed by the PROGENESIS QI software (Waters) to identify the proteins.

Arms & Interventions

Arms

Experimental: women with insulin resistance

An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

Experimental: patients with severe steatosis

An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

Experimental: General patients with insulin resistance

An analysis was made of patients, among men and women, with insulin resistance, among patients undergoing bariatric surgery

Experimental: Patients with above average CRP

An analysis was carried out of patients with CRP above the average, among patients undergoing bariatric surgery

Experimental: Patients with grade 1 obesity

An analysis was made of patients with grade 1 obesity, among patients undergoing bariatric surgery

Experimental: Patients with grade 2 obesity

An analysis was made of patients with grade 2 obesity, among patients undergoing bariatric surgery

Experimental: Patients with grade 3 obesity

An analysis was made of patients with grade 3 obesity, among patients undergoing bariatric surgery

Interventions

Procedure: - bariatric surgery

sleeve gastrectomy

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.